ZLAB Stock — Zai Lab Limited

Zai Lab Limited (ZLAB)

Updated October 16, 2026.

ZLAB is a Stock. Total return is -17.0% over the past 9.1 years, 267.3 points behind SPY at 250.3%.

Zai Lab Limited is a biopharmaceutical company focused on discovering, developing, and commercializing products in oncology, immunology, neuroscience, and infectious diseases. The company markets commercial products including Zejula for ovarian cancer, VYVGART for myasthenia gravis, NUZYRA for bacterial infections, and several other cancer and infection treatments, supported by partnerships with major pharmaceutical companies including Pfizer and Amgen. The company does not currently pay distributions.

ZLAB performance versus SPY

Price and return data through 2026-10-16.

Total return is -17.0% over the past 9.1 years, 267.3 points behind SPY at 250.3%. Over the past year its total return — price change plus distributions reinvested — is -19.6%. Its deepest 1-year drawdown was 44.1%.

ZLAB key facts

Asset type

Stock

Asset class

Equity

Inception date

09/20/2017

Distribution frequency

None

Last close

$23.19 (as of 2026-10-16)

Market cap

$2,603,453,827

Average volume

843206.0

Beta

0.724

Payout ratio

0.0%

EPS

$-1.70

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ZLAB risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 44.1%.

Who may consider ZLAB — and who may not

It is a weaker fit for investors who need monthly cash flow (ZLAB does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ZLAB

• All tickers starting with Z

Tagged: Healthcare.

Frequently asked questions